Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches

Executive Summary

This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.

You may also be interested in...



Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs

Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.

All To Play For: CAR-T Specialist Celyad’s Big Year

Celyad’s leadership team talks to Scrip about the critical nature of the coming months for its lead cancer therapy product, and CAR-T market differentiation.

BerGenBio Adds Another Brick To AXL Inhibitor Bemcentinib’s AML Potential

As the most advanced AXL inhibitor product in the global pipeline, BerGenBio’s bemcentinib has continued to show encouraging data in AML, following on from monotherapy trials last year.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC124291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel